The rapid escalation of antimicrobial resistance (AMR) has rendered conventional antibiotics increasingly ineffective, particularly in chronic wound management and implant-associated infections where biofilm formation impedes drug penetration and fosters multidrug-resistant pathogens. Functional nanomaterials—encompassing metallic and metal-oxide nanoparticles, carbon-based nanostructures, polymeric and hybrid nanocomposites, and stimuli-responsive systems—offer transformative solutions by enabling localized, sustained, and multimodal antimicrobial action. These nanoscale platforms disrupt bacterial membranes, generate reactive oxygen species (ROS), release therapeutic ions or payloads in a controlled manner, and integrate regenerative cues to accelerate tissue repair. In wound dressings, nanomaterial integration enhances antimicrobial efficacy, angiogenesis, and moisture balance, while advanced implant coatings deliver biofilm-resistant, osteoinductive, and infection-responsive surfaces without systemic toxicity. This review synthesizes advances from 2010 to 2025, emphasizing biofilm-disruption mechanisms, smart drug-release strategies, and the clinical translation of nanomaterial-enabled therapies. It critically evaluates biosafety, regulatory, and scalability challenges, while outlining future directions including AI-guided material design, personalized nanomedicine, and sustainable synthesis approaches. By uniting antimicrobial potency with regenerative functionality, functional nanomaterials represent a paradigm shift in combating AMR at the interface of infection control and tissue engineering.
No takes yet. Share an insight, caveat, or question.
Mb et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: